294 related articles for article (PubMed ID: 14769599)
1. Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration.
Jonas JB; Akkoyun I; Budde WM; Kreissig I; Degenring RF
Arch Ophthalmol; 2004 Feb; 122(2):218-22. PubMed ID: 14769599
[TBL] [Abstract][Full Text] [Related]
2. Intereye difference in exudative age-related macular degeneration with minimally classic or occult subfoveal neovascularization after unilateral intravitreal injection of triamcinolone acetonide.
Jonas JB; Spandau UH; Harder B; Vossmerbaeumer U; Kamppeter BA
Am J Ophthalmol; 2005 Jun; 139(6):1073-9. PubMed ID: 15953439
[TBL] [Abstract][Full Text] [Related]
3. Follow-up after intravitreal triamcinolone acetonide for exudative age-related macular degeneration.
Jonas JB; Spandau UH; Kamppeter BA; Harder B
Eye (Lond); 2007 Mar; 21(3):387-94. PubMed ID: 16410809
[TBL] [Abstract][Full Text] [Related]
4. Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide. A prospective comparative nonrandomized study.
Jonas JB; Degenring RF; Kreissig I; Friedemann T; Akkoyun I
Eye (Lond); 2005 Feb; 19(2):163-70. PubMed ID: 15218517
[TBL] [Abstract][Full Text] [Related]
5. Repeated intravitreal high-dosage injections of triamcinolone acetonide for diffuse diabetic macular edema.
Jonas JB; Spandau UH; Kamppeter BA; Vossmerbaeumer U; Harder B; Sauder G
Ophthalmology; 2006 May; 113(5):800-4. PubMed ID: 16530840
[TBL] [Abstract][Full Text] [Related]
6. Repeated intravitreal injection of triamcinolone for exudative age-related macular degeneration.
Jonas JB; Spandau UH; Kamppeter BA; Vossmerbaeumer U; Harder B
Ophthalmic Res; 2006; 38(6):324-8. PubMed ID: 17047404
[TBL] [Abstract][Full Text] [Related]
7. Duration of the effect of intravitreal triamcinolone acetonide in eyes with exudative age-related macular degeneration.
Jonas JB; Spandau UH; Kamppeter BA; Degenring RF; Kreissig I; Akkoyun I; Vossmerbaeumer U
J Ocul Pharmacol Ther; 2006 Jun; 22(3):194-9. PubMed ID: 16808681
[TBL] [Abstract][Full Text] [Related]
8. Prospective, randomized clinical trial of intravitreal triamcinolone treatment of neovascular age-related macular degeneration: one-year results.
Lee J; Freeman WR; Azen SP; Chung EJ; Koh HJ
Retina; 2007; 27(9):1205-13. PubMed ID: 18046226
[TBL] [Abstract][Full Text] [Related]
9. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results.
Gillies MC; Simpson JM; Luo W; Penfold P; Hunyor AB; Chua W; Mitchell P; Billson F
Arch Ophthalmol; 2003 May; 121(5):667-73. PubMed ID: 12742844
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal bevacizumab combined with intravitreal triamcinolone for therapy-resistant exudative age-related macular degeneration.
Tao Y; Jonas JB
J Ocul Pharmacol Ther; 2010 Apr; 26(2):207-12. PubMed ID: 20415625
[TBL] [Abstract][Full Text] [Related]
11. Photodynamic therapy and high-dose intravitreal triamcinolone to treat exudative age-related macular degeneration: 1-year outcome.
Ruiz-Moreno JM; Montero JA; Barile S; Zarbin MA
Retina; 2006; 26(6):602-12. PubMed ID: 16829800
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab versus triamcinolone acetonide for exudative age-related macular degeneration.
Jonas JB; Ihloff AK; Harder B; Kreissig I; Schlichtenbrede F; Libondi T; Spandau UH; Vossmerbaeumer U
Ophthalmic Res; 2009; 41(1):21-7. PubMed ID: 18849638
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration.
Danis RP; Ciulla TA; Pratt LM; Anliker W
Retina; 2000; 20(3):244-50. PubMed ID: 10872928
[TBL] [Abstract][Full Text] [Related]
14. Visual acuity change after intravitreal triamcinolone in various types of exudative age-related macular degeneration.
Jonas JB; Strueven V; Kamppeter BA; Harder B; Spandau UH; Schlichtenbrede F
J Ocul Pharmacol Ther; 2006 Oct; 22(5):370-6. PubMed ID: 17076632
[TBL] [Abstract][Full Text] [Related]
15. Factors influencing visual acuity after intravitreal triamcinolone acetonide as treatment of exudative age related macular degeneration.
Jonas JB; Kreissig I; Degenring RF
Br J Ophthalmol; 2004 Dec; 88(12):1557-62. PubMed ID: 15548812
[TBL] [Abstract][Full Text] [Related]
16. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial.
Gillies MC; Simpson JM; Billson FA; Luo W; Penfold P; Chua W; Mitchell P; Zhu M; Hunyor AB
Arch Ophthalmol; 2004 Mar; 122(3):336-40. PubMed ID: 15006845
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal triamcinolone acetonide for exudative age-related macular degeneration among Japanese patients.
Ito M; Okubo A; Sonoda Y; Yamakiri K; Sakamoto T
Ophthalmologica; 2006; 220(2):118-24. PubMed ID: 16491035
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal triamcinolone acetonide for exudative age related macular degeneration.
Jonas JB; Kreissig I; Hugger P; Sauder G; Panda-Jonas S; Degenring R
Br J Ophthalmol; 2003 Apr; 87(4):462-8. PubMed ID: 12642311
[TBL] [Abstract][Full Text] [Related]
19. Inter-eye difference in diabetic macular edema after unilateral intravitreal injection of triamcinolone acetonide.
Jonas JB; Harder B; Kamppeter BA
Am J Ophthalmol; 2004 Dec; 138(6):970-7. PubMed ID: 15629288
[TBL] [Abstract][Full Text] [Related]
20. Photodynamic therapy and high-dose intravitreal triamcinolone to treat exudative age-related macular degeneration: 2-year outcome.
Ruiz-Moreno JM; Montero JA; Zarbin MA
Retina; 2007; 27(4):458-61. PubMed ID: 17420698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
